Generic Drug Antitrust Payouts
Consumers May Qualify For Payouts From $96.5 Million Generic Drug Antitrust Settlements
Anonymous
Key Points
1
Investigators said corporate executives routinely communicated with one another to set prices and divide market share, providing evidence underlying the allegations of industrywide collusion.
2
The settlements also include Heritage Pharmaceuticals’ parent company, Emcure, which was not identified in the summary’s list of manufacturers.
3
Washington and Idaho were the only states in the coalition to secure restitution specifically for businesses affected by the alleged conspiracy; Washington businesses that indirectly purchased the drugs or reimbursed their cost may qualify.
4
Washington Attorney General Nick Brown said the agreement is intended to compensate consumers who were unlawfully overcharged and pledged that the state’s antitrust team would continue holding pharmaceutical companies accountable.
5
The multistate coalition has pursued a broader series of generic-drug antitrust cases since 2016, targeting additional companies and executives beyond the manufacturers covered by these settlements.
Consumers who bought certain generic prescription drugs between May 2009 and December 2019 may qualify for compensation from a $96.5 million settlement. Connecticut Attorney General announced that a federal court has approved a plan to distribute funds to eligible buyers after manufacturers including Glenmark, Lannett, Bausch, Apotex and Heritage agreed to settle antitrust claims. Washington Attorney General said the companies illegally colluded to limit competition and inflate prices on over 114 generic medications.
Eligible consumers can check the covered-drug list and file claims at AGGenericDrugs.com, by email at info@AGGenericDrugs.com, or by calling 1-866-290-0182. Washington and Idaho consumers also qualify if their employers purchased or reimbursed the affected drugs. The settlements mark a major victory in a broader campaign that began in 2016, with more cases against other drug makers still pending.
How Executives Rigged Generic Drug Prices
State investigators uncovered evidence that corporate executives regularly communicated to divide market share and set artificially high prices. Connecticut Attorney General William Tong said the executives "rigged the market and forced customers to pay higher prices for critical medication." Investigators reviewed millions of pages of corporate documents, phone records from 600+ sales staff, and co-conspirator testimony spanning the 10-year scheme.
The scheme affected over 114 generic drugs across antibiotics, heart medications, mental health treatments, and cancer drugs—including generic versions of Adderall, Celebrex, Prozac, and Zithromax. Some prices were inflated over 1,000%, making generic medications nearly as expensive as brand-name alternatives they were designed to replace.
Who Can Claim Money and How
Individual consumers qualify if they purchased any of the affected generic drugs between May 1, 2009, and December 31, 2019. Washington and Idaho went further—those states secured unique provisions allowing local businesses that indirectly purchased or reimbursed employees for the drugs to also claim compensation. The settlement covers residents of all 48 participating states and U.S. territories.
To file a claim, visit AGGenericDrugs.com and check the covered-drug list. Consumers can also submit claims by emailing info@AGGenericDrugs.com or calling 1-866-290-0182. The exact payout per person will depend on how many claims are filed. A federal court in Connecticut has preliminarily approved the distribution plan and oversees the process.
Five Drug Makers Settled; Others Still Face Trial
Glenmark Pharmaceuticals agreed to pay $29.6 million, the largest settlement in this wave. Lannett and Bausch combined to pay $17.85 million, while Apotex and Heritage Pharmaceuticals (including parent company Emcure) settled for the remaining funds. All settling manufacturers agreed to maintain compliance programs, adopt antitrust reforms, and cooperate as witnesses in ongoing trials.
Over 30 additional corporations and 25 individual executives remain defendants in related cases. Washington Attorney General Nick Brown pledged that the state's antitrust team would "continue holding pharmaceutical companies accountable." The coalition expects its first federal trial against non-settling defendants to begin in Hartford, Connecticut, in late 2026 or early 2027.
A Ten-Year Antitrust Campaign Gains Momentum
State attorneys general launched their investigation in 2016, alleging a industrywide conspiracy among generic drug makers. The coalition—led by Connecticut, Washington, Maryland, Pennsylvania, and New Jersey—has pursued multiple cases targeting different companies in waves. The $96.5 million in settlements announced in 2026 represents the first major victory, but investigators say far more is at stake.
The settlements require settling manufacturers to maintain corrective compliance for seven years. Remaining defendants face trial exposure, and analysts expect additional settlements as the case progresses. Connecticut Attorney General Tong said the coalition is "just getting started" in holding the generic drug industry accountable for years of inflated pricing that harmed consumers and healthcare systems.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
27
Articles
29
Reach
56
Topics
A
AnonymousAuthor
